LABANEB Inhalation Solution 5X2ml (N)

Introduction About LABANEB INHALATION SOLUTION

LABANEB INHALATION SOLUTION contains Arformoterol which belongs to the group of medicines called Bronchodilators. It is indicated for the long-term maintenance management of bronchoconstriction (obstruction of airways) in patients with chronic obstructive pulmonary disease (COPD), including emphysema (damage to lung alveoli causing frequent cough) and chronic bronchitis (chronic recurring lung disease with productive cough).

Chronic obstructive pulmonary disease refers to the group of chronic diseases of lung which causes block in the airways. The symptoms include wheezing, difficulty in breathing, cough, etc. Your doctor might ask you to take several diagnostic tests before starting the management with LABANEB INHALATION SOLUTION.

LABANEB INHALATION SOLUTION is not recommended for use in patients having asthma and not using medication for asthma control. LABANEB INHALATION SOLUTION should be used with caution in patients having liver, heart or thyroid problems, high blood pressure, epilepsy (fits) and diabetes.

Caution must be exercised while using LABANEB INHALATION SOLUTION in pregnant and breast-feeding women so, consult with your doctor before taking it. LABANEB INHALATION SOLUTION is generally not recommended for use in children and it should be used with caution in elderly patients (above 65 years of age).

The most common side effects of taking LABANEB INHALATION SOLUTION are chest or back pain, sinus or nasal congestion, diarrhoea, flu-like symptoms such as headache, fever, vomiting, tiredness. Consult your doctor for advice if any of the symptoms worsen or doesn’t improve.

Uses Of LABANEB INHALATION SOLUTION

• For the long-term maintenance management of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis

How LABANEB INHALATION SOLUTION Works

LABANEB INHALATION SOLUTION effectively relieves the bronchoconstriction where Arformoterol acts by activating certain receptors (beta 2 adrenergic receptors) and causes smooth muscle relaxation in lungs thereby widening the airways which makes breathing easier. LABANEB INHALATION SOLUTION also inhibits the release of inflammatory mediators thus, reducing the inflammation of the airways.

How to use LABANEB INHALATION SOLUTION

Take LABANEB INHALATION SOLUTION as advised by your physician. It is for oral inhalational use only. It is administered by nebulisation using standard nebuliser machine (with a face mask or mouthpiece) which is connected to an air compressor.

Your doctor will guide on how to use the nebuliser and will decide the correct dose and duration of LABANEB INHALATION SOLUTION for you depending upon your age, body weight and disease condition. Do not stop using LABANEB INHALATION SOLUTION unless your doctor advises you to stop.

Side Effects Of LABANEB INHALATION SOLUTION

How To Manage Side Effects

Diarrhea:

Keep yourself hydrated by drinking lots of fluids, such as water or fruit juice. Do not consume any medicine on your own without consulting your doctor. If symptom persists, contact your doctor.

Headache:

Apply hot or cold-water bag on your head. Try to take rest in a quiet and dark room. Drink tea or coffee. Apply a pain-relieving balm on your forehead and massage on scalp or head with mild pressure. If symptom persists, contact your doctor.

Warning & Precautions

Pregnancy

LABANEB INHALATION SOLUTION should be used with caution in pregnant woman or in woman planning to become pregnant as it is not known if it will harm the baby. Consult your physician before taking it.

Breastfeeding

LABANEB INHALATION SOLUTION should be used with caution in breastfeeding woman as it is not known if it passes through mother’s milk and if it can harm your baby. Consult your physician before taking it.

Liver

LABANEB INHALATION SOLUTION should be used with caution in patients having liver diseases. Consult your doctor for advice.

Allergy

Do not take LABANEB INHALATION SOLUTION if you are allergic to Arformoterol or Formoterol or any of the other ingredients of this medicine.

Lungs

LABANEB INHALATION SOLUTION is not recommended for use in patients having lung diseases such as asthma and not using medication for asthma control. Consult your doctor for advice.

Heart Disease

LABANEB INHALATION SOLUTION should be used with caution in patients having heart diseases or high blood pressure. Consult your doctor for advice.

Interactions

A. Drug - Drug interactions:

Before using LABANEB INHALATION SOLUTION, inform your doctor if you are taking any of the following medicines:

• other adrenergic drugs like phenylephrine, ephedrine, salbutamol, etc (used in many conditions like bronchodilation, smooth muscle contraction, etc)
• medicines used to manage acute exacerbations of asthma (Ex. aminophylline, theophylline)
• medicines used in autoimmune and inflammatory disease conditions (Ex. prednisolone, hydrocortisone)
• medicines used to remove excessive body fluids (Ex. furosemide, bumetanide)
• medicines used in depression (Ex. isocarboxazid, phenelzine, doxepin, amitriptyline)
• medicines used to manage heart problems (Ex. quinidine, procainamide, propranolol, atenolol)

Overdosage:

If you or anyone else accidentally use too much of LABANEB INHALATION SOLUTION, consult your doctor immediately or visit the nearby hospital. Symptoms of overdose include angina or chest pain, high or low blood pressure, increased or irregular heartbeat, nervousness, shaky movements of one or more parts of the body, headache, dry mouth, fast or fluttering heartbeat, muscle cramps, nausea, fatigue, dizziness, generally feeling unwell, increased blood sugar level and insomnia.

Synopsis

More Information

• Keep LABANEB INHALATION SOLUTION out of reach of children
• Store LABANEB INHALATION SOLUTION in the refrigerator at 2-8°C

FAQs About LABANEB INHALATION SOLUTION

What is LABANEB INHALATION SOLUTION and why is it given?

LABANEB INHALATION SOLUTION contains Arformoterol which belongs to the group of medicines called Bronchodilators. It is indicated for the long-term maintenance management of bronchoconstriction (obstruction of airways) in patients with chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.

How to use LABANEB INHALATION SOLUTION?

Use LABANEB INHALATION SOLUTION as advised by your physician. It is for oral inhalational use only. It is administered by nebulisation using standard nebuliser machine (with a face mask or mouthpiece) which is connected to an air compressor. Your doctor will guide on how to use the nebuliser and will decide the correct dose and duration of LABANEB INHALATION SOLUTION for you depending upon your age, body weight and disease condition.

Can LABANEB INHALATION SOLUTION be given to heart patients?

LABANEB INHALATION SOLUTION can cause irregular or fast heartbeat. Therefore, it should be used with caution in patients having heart problems and high blood pressure. Consult your doctor for advice. The physician will determine a proper dose or select a suitable alternative management for you.

Is it safe to use LABANEB INHALATION SOLUTION in asthma patients?

LABANEB INHALATION SOLUTION may cause worsening of asthma. Therefore, IT is not recommended for use in patients having asthma and not using medication for asthma control. Consult your doctor for advice. The physician will determine a proper dose or select a suitable alternative management for you.

What happens if I stop taking LABANEB INHALATION SOLUTION on my own?

Do not stop taking LABANEB INHALATION SOLUTION until your doctor has told to do so. Stopping the medicine before the completion of the management may worsen the symptoms. Talk with your doctor.

References

1. KD. Tripathi. CNS Stimulants and Cognition Enhancers. Essentials of medical pharmacology. Eighth edition. 2019. Page –517.

2. Paul King. Role of arformoterol in the management of COPD. NIH National Library of Medicine, National Centre for biotechnology information. PubMed Central. September 2008. [Accessed 14th September 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2629977/

3. James F. Donohue, Nicola A. Hanania, Barry Make, Matthew C. Miles, Donald A. Mahler, Lisa Curry, Robert Tosiello, Alistair Wheeler, Donald P. Tashkin. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. NIH National Library of Medicine, National Centre for biotechnology information. PubMed Central. June 2014. [Accessed 14th September 2022]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251615/

4. Arformoterol. NIH National Library of Medicine, National Centre for biotechnology information. PubChem. September 2022. [Accessed 14th September 2022]. https://pubchem.ncbi.nlm.nih.gov/compound/Arformoterol

5. Sunovion Pharmaceuticals Inc. U.S. Food & Drug Administration. [Revised in February 2014] [Accessed 14th September 2022]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021912s013lbl.pdf

6. Sun Pharmaceutical Medicare Limited. Arformoterol Tartrate. [Revised in December 2021]. [Accessed 14th September 2022]. https://sunpharma.com/usa/wp-content/uploads/sites/2/2022/06/Arformoterol-Tartrate-Inhalation-Solution-15-mcg-2-mL-PIL.pdf

7. Sunovion Pharmaceuticals Inc. Brovana (Arformoterol Tartrate). [Revised in May 2019]. [Accessed 14th September 2022]. https://www.brovana.com/brovana-approved-labeling-text.pdf

Useful Diagnostic Tests

• Pulmonary Function Test
• Chest X ray
• CT scan

Author Details

Written By Dr. Jeenal Rajani - Pharm.D.

Reviewed For Accuracy By Dr. Rajnikant - MBBS, MD (Physiology)

Last updated on 30 Nov 2022 | 03:12 PM(IST)